Results 61 to 70 of about 126,328 (301)

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]

open access: yes, 2016
BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA   +17 more
core   +3 more sources

Contemporary best practice in the management of malignant pleural effusion

open access: yesTherapeutic Advances in Respiratory Disease, 2018
Malignant pleural effusion (MPE) affects more than 1 million people globally. There is a dearth of evidence on the therapeutic approach to MPE, and not surprisingly a high degree of variability in the management thereof.
C. Koegelenberg   +3 more
semanticscholar   +1 more source

Malignant pleural effusion and cancer of unknown primary site: a review of literature.

open access: yesAnnals of Translational Medicine, 2019
Malignant pleural effusions (MPE) are most frequently (50-65%) noted from lung and breast cancers. They are commonly unilateral and are reflective of poorer prognosis. Cancer of unknown primary (CUP) account for 4-5% of all invasive cancers.
S. Awadallah   +3 more
semanticscholar   +1 more source

Struma Ovarii Associated with Pseudo- Meigs’Syndrome [PDF]

open access: yes, 2012
Struma ovarii is a specialized ovarian teratoma composed predominantly of mature thyroid tissue. It is associated with pleural effusion and ascites (Pseudo-Meigs’ syndrome) in 5% of cases.
Gangane, NM, Gulhane, SR, Sinha, RT
core   +1 more source

Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer

open access: yesThoracic Cancer, 2019
The aim of this study was to evaluate the usefulness of the presence of malignant pleural effusion (MPE) as a negative predictor of anti‐PD‐1 antibody efficacy.
R. Shibaki   +10 more
semanticscholar   +1 more source

A novel interleukin 36 gamma for diagnosing and differentiating malignant from infectious pleural effusion

open access: yesEgyptian Journal of Chest Disease and Tuberculosis
Background Pleural effusions can be caused by various diseases, making their diagnosis challenging. Light’s criteria are often used to distinguish transudative and exudative effusions.
Nashwa A. Amin   +6 more
doaj   +1 more source

Diagnostic significance of pleural fluid pH and pCO2

open access: yesEgyptian Journal of Chest Disease and Tuberculosis, 2015
The diagnosis of pleural effusion is still difficult. The presence of pleural effusion can be confirmed by radiological studies including simple chest radiography, ultrasonography, or computed tomography.
K.E. Sobhey, B.A. Naglaa
doaj   +1 more source

Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. [PDF]

open access: yes, 2017
Malignant mesothelioma is a rare cancer that arises from the mesothelial cells that line the pleural cavity and less commonly from the peritoneal lining of the abdomen and pelvis.
Bastian, Boris C   +10 more
core   +2 more sources

The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion. [PDF]

open access: yesPLoS ONE, 2016
The aim of our study was to evaluate the role of 18F-FDG PET/CT integrated imaging in differentiating malignant from benign pleural effusion.A total of 176 patients with pleural effusion who underwent 18F-FDG PET/CT examination to differentiate ...
Yajuan Sun   +3 more
doaj   +1 more source

Spectrum and outcome in patients with unilateral pleural effusion admitted in a tertiary care hospital

open access: yesJournal of Clinical and Scientific Research, 2022
Background: Unilateral pleural effusion is a challenge for a physician as the differential diagnosis is varied; sparse epidemiological data are available from India on this subject.
Neeraj Saini   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy